Abstract

BackgroundDuring the COVID-19 lockdown period in the United Kingdom that began on March 23, 2020, more than a quarter of a million people with cancer reported worsening mental health. Help to Overcome Problems Effectively (Hope) is a self-management program for people with cancer, designed to provide support for distress, unmet needs, and poor psychological health. In light of social distancing during the COVID-19 pandemic, digital delivery of the Hope Programme has become ever more vital for people with cancer. Previous pre-post studies of the digital Hope Programme have found reduced anxiety and depression and improved well-being for people with cancer. However, evaluation of this evidence has been limited by the lack of a control group in these previous studies.ObjectiveWe now present a protocol for a feasibility randomized controlled trial of the digital Hope Programme for people with cancer during the COVID-19 pandemic. Primary outcomes will be recruitment, dropout, and adherence rates, and estimations of sample and effect size. To detect signals of efficacy, secondary outcomes will be participant mental health and well-being.MethodsParticipants will be recruited by Macmillan Cancer Support (MCS) through their social media networks. The study will employ a feasibility wait-list randomized controlled trial (RCT) design, with people with cancer being randomized to join the digital Hope Programme immediately (intervention group [IG]) or join a 6-week waiting list (wait-list control group [WLCG]) with a 1:1 allocation ratio. Participants will complete digital measures of depression, anxiety, mental well-being, and confidence in managing their own health. Online questionnaires will be administered preprogram and 6 weeks postprogram.ResultsAll people who had requested access to the Hope Programme from MCS (N=61) will be invited to participate in the trial. Baseline data collection commenced in April 2020, and the Hope Programme began for the IG in May 2020 and for the WLCG in June 2020. Postprogram data collection was completed by the end of August 2020.ConclusionsThis feasibility study will provide data to inform the design of a future definitive trial. Wider-scale provision of the digital Hope Programme has potential to improve the lives of thousands of people with cancer and reduce the burden on health care providers during these unprecedented times.Trial RegistrationISRCTN Registry ISRCTN79623250; http://www.isrctn.com/ISRCTN79623250International Registered Report Identifier (IRRID)DERR1-10.2196/24264

Highlights

  • Background and RationaleThe COVID-19 pandemic has created additional challenges for people with cancer, both in terms of physical and mental health

  • The study will employ a feasibility wait-list randomized controlled trial (RCT) design, with people with cancer being randomized to join the digital Help to Overcome Problems Effectively (Hope) Programme immediately or join a 6-week waiting list with a 1:1 allocation ratio

  • Baseline data collection commenced in April 2020, and the Hope Programme began for the intervention group (IG) in May 2020 and for the wait-list control group (WLCG) in June 2020

Read more

Summary

Introduction

Background and RationaleThe COVID-19 pandemic has created additional challenges for people with cancer, both in terms of physical and mental health. A significant number of patients with cancer experience long-term negative impacts on their psychological well-being and mental health, including hypervigilance, anxiety, posttraumatic stress, and depression [9,10,11,12,13,14]; 2 years postdiagnosis, up to 20% met criteria for major depression and up to 40% met criteria for an anxiety disorder [13,14]. Many of these difficulties are experienced long-term, after regular contact with health care professionals has ceased, which leads to many patients feeling vulnerable and unsupported [5,7,8]. Evaluation of this evidence has been limited by the lack of a control group in these previous studies

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call